

15 Jul 2024 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Q1's top 10 drugs; Pfizer's R&D leadership succession; Lilly bolsters IBD pipeline; first half deal volume up but value down; and EU firms' China sentiment plummets.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 July 2024, including: Q1's top 10 drugs; [Pfizer Inc.](#)'s R&D leadership succession; [Eli Lilly and Company](#) bolsters IBD pipeline; first half deal volume up but value down; and EU firms' China sentiment plummets.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Top 10 Drugs Q1 2024: Keytruda Reigns, Trikafta Debuts](#)" - Scrip, 5 Jul, 2024.)

(Also see "[Pfizer's Dolsten Plans Exit, Ushering In R&D Transition](#)" - Scrip, 9 Jul, 2024.)

(Also see "[Lilly To Bolster IBD Pipeline With \\$3.2bn Morphic Bid](#)" - Scrip, 8 Jul, 2024.)

(Also see "[Deal Volume Up, Value Down During The First Half](#)" - Scrip, 10 Jul, 2024.)

(Also see "[EU Firms' China Sentiment Plummets, China Go-Global Push Hits Reality Check](#)" - Scrip, 4 Jul, 2024.)

[Click here to explore this interactive content online](#) 